Guggenheim Capital LLC Tcr2 Therapeutics Inc. Transaction History

Guggenheim Capital LLC

  • $14 Billion
  • Q1 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$1.86 - $3.75 $124 - $251
-67 Reduced 0.63%
10,622 $19,000
Q2 2022

Aug 15, 2022
SELL
$2.11 - $2.94 $1,297 - $1,808
-615 Reduced 5.44%
10,689 $31,000
Q1 2022

May 16, 2022
SELL
$2.4 - $4.71 $81 - $160
-34 Reduced 0.3%
11,304 $31,000
Q4 2021

Feb 14, 2022
BUY
$4.58 - $8.34 $51,928 - $94,558
11,338 New
11,338 $53,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Guggenheim Capital LLC Portfolio

Follow Guggenheim Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email